Multiple organ failure due to statin rhabdomyolysis has been previously reported, and concurrent administration of drugs that interfere with CYP3A, such as lopinavir and ritonavir, might increase the risk of liver toxicity.(24) Similarly, COVID-19 can cause myalgia and increase liver enzymes, potentially leading to an increased risk of these side effects.(25) The included studies did not provide sufficient data to evaluate safety outcomes. The gene discussed is CYP3A4; the disease is rhabdomyolysis.